SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 10.79% in the revenue at Rs. 21482.23 millions was reported in the March 2024 quarter as compared to Rs. 19390.48 millions during year-ago period.The Total Profit for the quarter ended March 2024 of Rs. 46136.95 millions grew from Rs.-1374.69 millionsOperating Profit saw a handsome growth to 12837.18 millions from 4506.36 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 21482.23 19390.48 10.79 78911.19 82206.62 -4.01 78911.19 82206.62 -4.01
Other Income 7862.70 2329.65 237.51 11680.24 9859.39 18.47 11680.24 9859.39 18.47
PBIDT 12837.18 4506.36 184.87 24096.87 24587.06 -1.99 24096.87 24587.06 -1.99
Interest 833.85 588.60 41.67 2771.10 2068.16 33.99 2771.10 2068.16 33.99
PBDT 63472.46 -2665.96 -2480.85 72029.08 17560.22 310.18 72029.08 17560.22 310.18
Depreciation 524.01 467.29 12.14 2021.62 1841.48 9.78 2021.62 1841.48 9.78
PBT 62948.45 -3133.25 -2109.05 70007.46 15718.74 345.38 70007.46 15718.74 345.38
TAX 16811.50 -1758.56 -1055.98 18334.55 3631.05 404.94 18334.55 3631.05 404.94
Deferred Tax 6257.71 -2605.10 -340.21 7834.63 -238.26 -3388.27 7834.63 -238.26 -3388.27
PAT 46136.95 -1374.69 -3456.17 51672.91 12087.69 327.48 51672.91 12087.69 327.48
Equity 282.19 282.17 0.01 282.19 282.17 0.01 282.19 282.17 0.01
PBIDTM(%) 59.76 23.24 157.13 30.54 29.91 2.10 30.54 29.91 2.10

Glenmark Pharma. Share Price

2153.20 -26.65 (-1.22%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: